Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the proposed restrictions on puberty blockers will apply to those already using these medications.

In May 2024, a three-month emergency order restricting the sale and supply of Gonadotrophin-Releasing Hormone Analogues (puberty blockers) was introduced in Great Britain and was due to expire on 2 September 2024.

On 22 August 2024, the Government laid a further Order to renew the restrictions in Great Britain. As the Northern Ireland First Minister and Deputy First Minister provided their agreement for the Minister of Health to co-sign the order, the restrictions also extend to Northern Ireland for the first time.

Ensuring that care is safe, evidence-based and appropriate was the driving force behind the decision by my rt. Hon. Friend, the Secretary of State for Health and Social Care. The Cass Review was categorically clear that there is not enough evidence on the long-term impact of using puberty blockers to treat gender incongruence to know whether they are safe or if children benefit from them.

The Order prohibits the sale and supply of puberty blockers for any purposes to those under 18 against prescriptions from prescribers registered in the European Economic Area (EEA) or Switzerland. For private prescriptions issued from registered prescribers in the United Kingdom, the Order prohibits the sale or supply of puberty blockers for gender incongruence or dysphoria to children under 18 years old not already on a course of treatment with them. Patients receiving these medicines for other uses, for example precocious puberty, can continue to access them.

If a young person has already been prescribed these medicines, for gender dysphoria or incongruence in the six months prior to 3 June 2024 in Great Britain or 27 August 2024 in Northern Ireland, they can continue to do so, providing their prescription is now issued by a UK registered prescriber. They are strongly advised to meet with their prescribing clinician to fully understand the safety risks. For those patients accessing prescriptions from an EEA registered prescriber, they can seek help from a UK private provider or see their general practitioner.